TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05807139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Stages); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone and its matched placebo will be encapsulated into hard gelatin capsules, in same color, size and taste, to allow blinding.~Participants will receive 2x50 mg/day, 2x100 mg, and 2x200 mg/day in three sessions (Stages); these Visits always occur in ascending order of dosage. In the remaining session, participants receive the placebo.~Spironolactone is approved by the FDA, commercially available, and used in clinical practice for the treatment of hypertension, NYHA Class III-IV heart failure, edema in cirrhotic patients, and primary hyperaldosteronism. Comprehensive information about spironolactone, including its pharmacological properties, are provided in the Prescribing Information.
Study: NCT06701591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Participants will be seated on a chair, KT will be applied bilaterally at the end of the expiration on the fifth to sixth and ninth to tenth intercostal muscles transversally and on the anterior and posterior axillary line longitudinally with 50% tension. In order to stimulate the muscle and support the function, the stimulation technique is usually applied from the origin to the insertion of the muscle with the recommended stretching of 25 to 50%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest physical therapy
Description: The chest physical therapy program is consisted of deep breathing exercises, postural drainage, and cough.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chest physical therapy
Description: The chest physical therapy program is consisted of deep breathing exercises, postural drainage, and cough.
Study: NCT06599255

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-guided RSB and TAPB by one-puncture technique.
Description: The probe will be positioned transversely in the midline of the abdomen, between the xiphoid process and the umbilicus, revealing the linea alba. It was then moved outward along the costal margin, demonstrating the rectus abdominis overlapping the transverse abdominis. A 22-gauge, 120-mm ultrasound-visible block needle will be inserted from the inner side . Under direct vision, we will reach the posterior rectus abdominis sheath and pierced the anterior layer of the posterior sheath. Saline was injected to adjust its position. After that, 15 mL of 0.25% bupivacaine will be administered (aspiration was performed for every 5 mL injection), and we will observe the local anesthetic spreading inward . Then, the needle will break through the posterior layer of the tendon, and saline will be injected to confirm the needle's placement in the transversus abdominis plane. After confirming the tip placement, 15 mL of 0.25% bupivacaine will be slowly injected. The needle tip will be advanced al

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: multipont
Description: , the probe will be moved outward along the costal margin until the external oblique muscle, internal oblique muscle, and transverse abdominis muscle will be visible \[9\]. The needle will be inserted in-plane until the tip was positioned in the plane between the internal oblique muscle and the transverse abdominis muscle. Then, 15 mL of 0.25% bupivacaine will be injected . The contralateral nerve block will be performed using the same method and volume of anesthetic solution.~For the RSB, the same technique will be done as one puncture technique. Then, 15 mL of 0.25% bupivacaine will be injected . The contralateral nerve block will be performed using the same method and volume of anesthetic solution.
Study: NCT06701331

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets taken orally once a day (Or equivalent oral solution taken two times a day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Tablets taken orally once a day (Or equivalent oral solution taken two times a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablets taken orally once a day (Or equivalent oral solution taken two times a day)
Study: NCT06627192

Intervention type: PROCEDURE
Intervention: NSPT, clinical and biochemical assesment
Description: Biochemical assessment using ELISA kit for Endcan and TNF alpha GCF sample

Intervention type: PROCEDURE
Intervention: NSPT, clinical and biochemical assesment
Description: Biochemical assessment using ELISA kit for Endcan and TNF alpha GCF sample
Study: NCT06627231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56286
Description: Oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TEV-56286
Description: Oral capsule
Study: NCT06627959

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Statseal
Description: This is a vascular closure device which works independently of the clotting cascade to seal access sites

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Figure of eight suture
Description: The figure of eight suture is commonly used for vascular access closure
Study: NCT06634043

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally Advanced Tunel + ADM (Novomatrix®)
Description: ADM (Novomatrix®) will be used alone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Tunel + ADM (Novomatrix®) + L-PRF
Description: ADM in combination with L-Prf will be applied
Study: NCT06634381

Intervention type: BEHAVIORAL
Intervention: CRF Visual Aid
Description: After all qualitative interviews and associated quantitative data analysis are complete, the visual aid will be created to illustrate, through a type of Venn Diagram, how the data are related.

Intervention type: BEHAVIORAL
Intervention: CRF Visual Aid
Description: After all qualitative interviews and associated quantitative data analysis are complete, the visual aid will be created to illustrate, through a type of Venn Diagram, how the data are related.
Study: NCT06632951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livmoniplimab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livmoniplimab
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV Infusion
Study: NCT06633562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nezavist SDD
Description: Formulated as a spray dried dispersion (SDD) suspended in a flavored diluent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nezavist SDD
Description: Formulated as a spray dried dispersion (SDD) suspended in a flavored diluent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nezavist SDD
Description: Formulated as a spray dried dispersion (SDD) suspended in a flavored diluent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nezavist SDD
Description: Formulated as a spray dried dispersion (SDD) suspended in a flavored diluent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulated in a diluent that matches the Nezavist SDD suspension in appearance.
Study: NCT06492564

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 omicron virus dose arm 1
Description: Low dose, approximately 10\^4 TCID50/mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 omicron virus dose arm 2
Description: Medium dose, approximately 10\^5 TCID50/mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 omicron virus dose arm 3
Description: High dose, approximately 10\^6 TCID50/mL
Study: NCT06633445

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A injection in lateral pterygoid muscle
Description: * Needle insertion guide will be placed on upper teeth.~* Needle will be inserted from needle insertion sleeve and 25-30 units of botulinum toxin type A will be injected.~* Aspiration will be done before injection, and then, the patient will be asked to manipulate the mandible to activate the lateral pterygoid muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: botox injection in lateral pterygoid muscle
Description: * A 27- gauge needle electrode will be inserted lateral to the maxillary tuberosity, just above the maxillary molars to inject 25-30 units of botulinum toxin type A under electromyographic guidance.~* Aspiration will be done before injection, and then the patient will be asked to manipulate the mandible to activate the lateral pterygoid muscle.~* The intramuscular injection will be confirmed when the electromyographic device produces a distinct loud sound.
Study: NCT06619717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: Three treatments with hyperbaric oxygen therapy. The exact parameters of each dive will be left to individual clinicians. Commonly used treatments would be:~Weaver protocol, or similar (i.e. 100% oxygen at 3 atmospheres for 90 minutes with two 10-minute air breaks every 30 minutes. Repeat this every 8 hours until 3 treatments are complete.)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen Therapy
Description: Single treatment with hyperbaric oxygen. Exact parameters left to treating physician but commonly: 100% oxygen at 2.8 atmospheres for 30 minutes followed by a 10-minute air break, then 100% oxygen at 2 atmospheres for 60 minutes with one 10-minute air break after 30 minutes
Study: NCT04805814

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CMR results disclosed
Description: The results of the CMR are disclosed, and used to guide management

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: CMR performed but results not disclosed
Description: The results of the CMR are not disclosed, and management is angiography-guided
Study: NCT06132048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MuCopilot mobile application
Description: MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life
Study: NCT06137157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR12-351
Description: Topical ointment containing ATR12-351, a LEKTI-secreting strain of S. epidermidis
Study: NCT06049355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo Exercise Together exercise program, a supervised group exercise program delivered online, using a live remote format

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT06606379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I1 (Intervention)
Description: Resin ring (DR- Resin ring, Egypt)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I2 (Intervention)
Description: Elliot separator (Pfingst \& Co, South Plainfield, NJ, USA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I3 (Intervention)
Description: Stainless Steel Metal ring (TOR VM ring, Moscow, Russia)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C (comparator)
Description: Nickel titanium 3D-fusion ring (Garrison, USA)
Study: NCT06608758

Intervention type: BEHAVIORAL
Intervention: Electonic health record prompts with education
Description: 1). A baseline audit will be conducted of uses of Current Procedural Technology (CPT) Evaluation and Management (E/M) codes and evaluate for differences in complexity of CPT E/M code use for patients with disabilities (PWD) aged 3-89 years old with specific disabilities versus patients aged 3-89 without the specific disabilities.~Using analyses of data, chart reviews, staff interviews and mock tracers, a frame of themes underlying CPT code differences will be co-produced to develop algorithms to identify patients with the specified disabilities at risk. Case studies for education on DO, and EHR prompts, alerts, and decision supports related to the algorithms will be co-produced along with education on the EHR materials. Evaluate for change in use of CPT E/M among PWD after implementation of algorithms and EHR prompts, alerts and decision support will be conducted post-intervention.

Intervention type: OTHER
Intervention: Standard of care
Description: Patients without disabilities will receive standard care related to electronic health record prompts, alerts, and decision supports.
Study: NCT06659068

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seluang fish oil (Rasbora argyrotaenia) and synbiotic
Description: The patients received seluang fish oil (Rasbora argyrotaenia) and synbiotics (containing Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, Bifidobacterium bifidum R0071 20% and frukto-oligosaccharide 80 mg) supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received placebo capsules
Study: NCT04322305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin will be provided in 75 and 100 mg capsules twice daily for a maximum dose of 600 mg/day or the maximum tolerated dose over the 8 week medication phase and followed by a one week taper.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be provided twice daily over 8 weeks and one week taper..
Study: NCT05434065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg
Description: Using celecoxib (200 mg/day) for 21 days starting within 6 hours after onset of ICH
Study: NCT06607614

Intervention type: OTHER
Intervention: Colorectal Cancer Screening Fecal Immunochemical Test
Description: Fecal Immunochemical Test
Study: NCT06606509

Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring System (GX-01S)
Description: Patients with Type 1 Diabetes Mellitus (T1DM) will receive Continuous Glucose Monitoring System (GX-01S) for seven days.
Study: NCT06598228

Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: no intervention

Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: no intervention

Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: no intervention
Study: NCT04505553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture Therapy
Description: Undergo acupuncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure Therapy
Description: Undergo acupressure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Cryotherapy
Description: Undergo oral cryotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Cryotherapy
Description: Undergo oral cryotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT05827549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blincyto
Description: Vincristine 1.5mg/m2, L-asparaginase 6,000 IU/m2 Idarubicin 10mg/m2 will be administered for induction therapy. Ifosfamide 1.8g/m2 Etoposide 100mg/m2 will be administered for consolidation therapy, then patients will be sorted into groups depend on their potential risk and Blinatumomab IV will be administered over 28 days. Intensification course will be administered 4 times repeated. 1. etoposide 100mg/m2 Ifosfamide 3.4g/m2 with MESNA / 2.oral 6-mercaptopurine 50mg/m2, methotrexate 25mg/m2 / 3.Ara-C 1.0g/m2, Idarubicin 5mg/m2 / 4.vincristine 2mg/m2 are the courses for repetition.
Study: NCT05980104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered Relief
Description: The participants will attend an online pain relief skills intervention (Empowered Relief). The two-hour group session is delivered by a certified instructor and includes pain neuroscience education, 3 core pain management skills, experiential exercises, completion of a personalized plan for empowered relief. Participants download a binaural relaxation audio file for daily use.
Study: NCT06411912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIDO-361
Description: Tablets containing 100mg of NIDO-361 for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablets
Study: NCT05846425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nose-breathing training
Description: 13 days of controlled nose-breathing training at a specific frequency with a duration of approximately 15 min a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouth-breathing training
Description: 13 days of controlled mouth-breathing training at a specific frequency with a duration of approximately 15 min a day
Study: NCT04703608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin 0.3-0.4mg/Kg daily for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin 0.3-0.4mg/Kg daily for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP
Description: Aspirin 150mg daily for 28 days or until hospital discharge (whichever is sooner)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Non-identical placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-identical placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-identical placebo
Study: NCT05774223

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)-active
Description: Active intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)-sham
Description: Sham intermittent TBS (iTBS) will be applied to the left DLPFC at 80% of the resting motor threshold (rMT) (Hoy et al., 2016). The coil will be placed perpendicular to the left DLPFC. A stimulation, where 3-pulse at 50 Hz will be given, will repeat every 10 s for a total of 190 s (600 pulses in total) (Huang et al., 2005). The left DLPFC stimulation site will be determined using the neuronavigator system (lDLPFC, x-38, y+44, z+26).
Study: NCT05734001

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ROTEM Tests
Description: This group will undergo ROTEM based correction. ROTEM bcorrection will be based on the following protocol~1. EXTEM CT \> 80 sec - FFP will be transfused at 15 ml/kg MCF \< 35 mm- Platelet will be transfused at 10 ml/kg~2. FIBTEM MCF \< 7 mm- Cryoprecipitate will be transfused at 5 ml/kg

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Haemostatic Tests
Description: To prevent bleeding during the procedure, one group will receive prophylactic transfusion of either FFP, Platelet or Cryoprecipitate based on the following protocol~1. If INR: \> 2.5 FFP will be transfused at 15 ml/kg~2. If Platelet Count is 20,000/mm3-50,000/mm3 RDPC will be transfused at 10 ml/kg~3. If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg
Study: NCT04048707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin solution
Description: Intravenous suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin solution
Description: Intravenous suspension
Study: NCT06049355

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational materials
Study: NCT06395753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 4228
Description: Administered as IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 4228
Description: Administered as IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 4228
Description: Administered as IM injection.
Study: NCT06691984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xaluritamig
Description: Short-term IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabazitaxel
Description: IV infusion
Study: NCT05763550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK16149 20mg BID
Description: HSK16149 20mg, orally twice a day, treatment period; 4-weeks fixed dose.
Study: NCT05153421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: All'InCath CBC 035M Balloon Dilatation Catheter
Description: Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography with single balloon dilatation catheter.